Medhat Farwati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Medhat Farwati has a total of 130 co-authors. Here are the top co-authors by number of shared publications:
Bryan Baranowski
Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute , 9500 Euclid Ave., Cleveland Clinic, Cleveland, OH 44195
7 shared publications- Oussama Wazni
Cardiac Electrophysiology and Pacing Section, Department of Cardiovascular Medicine, Cleveland Clinic, Cleveland, Ohio, USA
7 shared publications Mandeep Bhargava
Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute , 9500 Euclid Ave., Cleveland Clinic, Cleveland, OH 44195
6 shared publications- Samir R. Kapadia
Cleveland Clinic
6 shared publications - Thomas D. Callahan
Cleveland Clinic
6 shared publications - Walid I. Saliba
Department of Cardiovascular Medicine, Cleveland Clinic, OH (H.N., M.S., A.A.H., S.N., P.S., W.I.S., O.M.W.).
6 shared publications
Latest Publications
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (1) , e014157
Factors Influencing Lesion Titration in a Monopolar Pulsed-Field Ablation Point Catheter: A Preclinical Study
BACKGROUND: Despite the rise of pulsed-field ablation (PFA), predicting and titrating lesion geometry remains challenging. This study aimed to find modifiable parameters that can accurately and repeatedly predict focal PFA lesions across a range of dimensions and to develop a model to predict lesion geometry. METHODS: An in vivo study was performed in 9 swine using an investigational dual-energy contact-force focal catheter with local impedance. Ablations were performed endocardially in the right and left ventricles using settings specifically selected to provide a wide range of lesion dimensions. Predefined PFA applications (1, 2, or 4) were delivered while maintaining different contact-force values (5–45 g). Four different voltages were used (1.0, 1.4, 2.0, and 2.2 kV). Following a 1-week survival period, the animals were euthanized for histopathologic examination. RESULTS: In the study characterization data set, a total of 78 PFA lesions were analyzed. Lesion depth ranged from 1.4 mm to 12.3 mm, while lesion width ranged from 3.3 mm to 21.2 mm. All 3 tested parameters—contact force, number of applications, and voltage—demonstrated a positive linear correlation with lesion depth ( P R =0.83; P R =0.76; P <0.0001). A perpendicular catheter orientation was correlated with deeper lesions than a parallel orientation. No ST-segment elevations or sustained ventricular arrhythmias were observed. CONCLUSIONS: Our findings demonstrate that PFA can be effectively titrated and predicted using the Focal FARAPULSE Index Model to create lesions of varying depths (1–12 mm), with these results being specific to the proprietary waveform and catheter used.
- 1 January 2026
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 19 (1) , e014157
Factors Influencing Lesion Titration in a Monopolar Pulsed-Field Ablation Point Catheter: A Preclinical Study
BACKGROUND: Despite the rise of pulsed-field ablation (PFA), predicting and titrating lesion geometry remains challenging. This study aimed to find modifiable parameters that can accurately and repeatedly predict focal PFA lesions across a range of dimensions and to develop a model to predict lesion geometry. METHODS: An in vivo study was performed in 9 swine using an investigational dual-energy contact-force focal catheter with local impedance. Ablations were performed endocardially in the right and left ventricles using settings specifically selected to provide a wide range of lesion dimensions. Predefined PFA applications (1, 2, or 4) were delivered while maintaining different contact-force values (5–45 g). Four different voltages were used (1.0, 1.4, 2.0, and 2.2 kV). Following a 1-week survival period, the animals were euthanized for histopathologic examination. RESULTS: In the study characterization data set, a total of 78 PFA lesions were analyzed. Lesion depth ranged from 1.4 mm to 12.3 mm, while lesion width ranged from 3.3 mm to 21.2 mm. All 3 tested parameters—contact force, number of applications, and voltage—demonstrated a positive linear correlation with lesion depth ( P R =0.83; P R =0.76; P <0.0001). A perpendicular catheter orientation was correlated with deeper lesions than a parallel orientation. No ST-segment elevations or sustained ventricular arrhythmias were observed. CONCLUSIONS: Our findings demonstrate that PFA can be effectively titrated and predicted using the Focal FARAPULSE Index Model to create lesions of varying depths (1–12 mm), with these results being specific to the proprietary waveform and catheter used.
- Open Access
- 18 November 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Intracardiac echocardiography guided anatomical approach to cardioneuroablation: feasibility and outcomes
Aims: Anatomical studies have documented a close topographical relationship between the ganglionated plexi (GP) containing parasympathetic inputs to the sinus node (SN) and atrioventricular node (AVN) and the epicardial fat pads (FPs) within the Waterston’s interatrial groove. We aimed to investigate the feasibility and outcomes of a novel anatomical approach to cardioneuroablation (CNA) that targets the atrial areas adjacent to the interatrial FPs identified with intracardiac echocardiography (ICE). Methods and results: About 17 patients [37.3 ± 10.2 years, 47% female] undergoing CNA for recurrent vasovagal syncope and documented sinus pauses (n = 13, 76%) and/or AVN block (AVB, n = 4, 16%) were included. The right superior RS-FP containing the RS-GP (target for SN vagal denervation) and the right inferior RI-FP containing the RI-GP (target for AVN vagal denervation) were identified with ICE and reconstructed on a 3D electroanatomic map. At baseline, all patients had provocable sinus pauses/AVB with extracardiac high-frequency vagal stimulation (ECVS). The target FPs could be identified in all patients and were adjacent to septal LA and RA sites covering an average surface area of 3.7 ± 1.4 cm2 and 2.97 ± 1.21 cm2, respectively. A total of 33 ± 15 RF ablations (30–40W, 60 s) were delivered to cover the target LA/RA area. A > 25% shortening of the PP interval was observed within the first 1–2 RF lesions in all cases. After ablation, complete abolition of sinus pauses/AVB response with ECVS was achieved in all patients, and 2 mg of atropine infusion resulted in no PP/PR interval change. After a median follow-up of 12 months (range 4–25 months), 16 patients (94%) remained free of recurrent symptoms (1 patient underwent repeat CNA for recurrent pre-syncope and AVB, 1 patient underwent PPM implant following ECG recording of asymptomatic diurnal AVB). Conclusion: An ICE-guided anatomical approach to CNA targeting visible FPs at the Waterston’s groove is a feasible and effective strategy to achieve SN/AVN vagal denervation, with good outcomes at mid-term follow-up.
- 18 November 2025
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 27 (12)
Open AccessIntracardiac echocardiography guided anatomical approach to cardioneuroablation: feasibility and outcomes
Aims: Anatomical studies have documented a close topographical relationship between the ganglionated plexi (GP) containing parasympathetic inputs to the sinus node (SN) and atrioventricular node (AVN) and the epicardial fat pads (FPs) within the Waterston’s interatrial groove. We aimed to investigate the feasibility and outcomes of a novel anatomical approach to cardioneuroablation (CNA) that targets the atrial areas adjacent to the interatrial FPs identified with intracardiac echocardiography (ICE). Methods and results: About 17 patients [37.3 ± 10.2 years, 47% female] undergoing CNA for recurrent vasovagal syncope and documented sinus pauses (n = 13, 76%) and/or AVN block (AVB, n = 4, 16%) were included. The right superior RS-FP containing the RS-GP (target for SN vagal denervation) and the right inferior RI-FP containing the RI-GP (target for AVN vagal denervation) were identified with ICE and reconstructed on a 3D electroanatomic map. At baseline, all patients had provocable sinus pauses/AVB with extracardiac high-frequency vagal stimulation (ECVS). The target FPs could be identified in all patients and were adjacent to septal LA and RA sites covering an average surface area of 3.7 ± 1.4 cm2 and 2.97 ± 1.21 cm2, respectively. A total of 33 ± 15 RF ablations (30–40W, 60 s) were delivered to cover the target LA/RA area. A > 25% shortening of the PP interval was observed within the first 1–2 RF lesions in all cases. After ablation, complete abolition of sinus pauses/AVB response with ECVS was achieved in all patients, and 2 mg of atropine infusion resulted in no PP/PR interval change. After a median follow-up of 12 months (range 4–25 months), 16 patients (94%) remained free of recurrent symptoms (1 patient underwent repeat CNA for recurrent pre-syncope and AVB, 1 patient underwent PPM implant following ECG recording of asymptomatic diurnal AVB). Conclusion: An ICE-guided anatomical approach to CNA targeting visible FPs at the Waterston’s groove is a feasible and effective strategy to achieve SN/AVN vagal denervation, with good outcomes at mid-term follow-up.
- 25 March 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (5) , 595-602
Cryoballoon pulmonary vein isolation versus radiofrequency ablation of the pulmonary veins and left atrial posterior wall: Patient‐reported outcomes
Background: Data are lacking on patient‐reported outcomes (PRO) following cryoballoon ablation (CBA) versus radiofrequency ablation (RFA). We sought to evaluate QoL and clinical outcomes of cryoballoon pulmonary vein isolation only (CRYO‐PVI‐ONLY) versus RFA with PVI and posterior wall isolation (RF‐PVI+PWI) in a large prospective PRO registry. Methods: Patients who underwent AF ablation (2013–2016) at our institution were enrolled in an automated, prospectively maintained PRO registry. CRYO‐PVI‐ONLY patients were matched (1:1) with RF‐PVI+PWI patients based on age, gender, and type of AF (paroxysmal vs. persistent). QoL and clinical outcomes were assessed using PRO surveys at baseline and at 1‐year. The atrial fibrillation symptom severity scale (AFSSS) was the measure for QoL. Additionally, we assessed patient‐reported clinical improvement, arrhythmia recurrence, and AF burden (as indicated by AF frequency and duration scores). Results: A total of 296 patients were included (148 in each group, 72% paroxysmal). By PRO, a significant improvement in QoL was observed in the overall study population and was comparable between CRYO‐PVI‐ONLY and RF‐PVI+PWI (baseline median AFSSS of 11.5 and 11; reduced to 2 and 4 at 1 year, respectively; p = 0.44). Similarly, the proportion of patients who reported improvement in their overall QoL and AF related symptoms was high and similar between the study groups [92% (CRYO‐PVI‐ONLY) vs. 92.8% (RF‐PVI+PWI); p = 0.88]. Arrhythmia recurrence was significantly more common in the CRYO‐PVI‐ONLY group (39.7%) compared to RF‐PVI+PWI (27.7 %); p = 0.03. Comparable results were observed in paroxysmal and persistent AF. Conclusion: CRYO‐PVI‐ONLY and RF‐PVI+PWI resulted in comparable improvements in patient reported outcomes including QoL and AF burden; with RF‐PVI+PWI being more effective at reducing recurrences.
- 25 March 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (5) , 595-602
Cryoballoon pulmonary vein isolation versus radiofrequency ablation of the pulmonary veins and left atrial posterior wall: Patient‐reported outcomes
Background: Data are lacking on patient‐reported outcomes (PRO) following cryoballoon ablation (CBA) versus radiofrequency ablation (RFA). We sought to evaluate QoL and clinical outcomes of cryoballoon pulmonary vein isolation only (CRYO‐PVI‐ONLY) versus RFA with PVI and posterior wall isolation (RF‐PVI+PWI) in a large prospective PRO registry. Methods: Patients who underwent AF ablation (2013–2016) at our institution were enrolled in an automated, prospectively maintained PRO registry. CRYO‐PVI‐ONLY patients were matched (1:1) with RF‐PVI+PWI patients based on age, gender, and type of AF (paroxysmal vs. persistent). QoL and clinical outcomes were assessed using PRO surveys at baseline and at 1‐year. The atrial fibrillation symptom severity scale (AFSSS) was the measure for QoL. Additionally, we assessed patient‐reported clinical improvement, arrhythmia recurrence, and AF burden (as indicated by AF frequency and duration scores). Results: A total of 296 patients were included (148 in each group, 72% paroxysmal). By PRO, a significant improvement in QoL was observed in the overall study population and was comparable between CRYO‐PVI‐ONLY and RF‐PVI+PWI (baseline median AFSSS of 11.5 and 11; reduced to 2 and 4 at 1 year, respectively; p = 0.44). Similarly, the proportion of patients who reported improvement in their overall QoL and AF related symptoms was high and similar between the study groups [92% (CRYO‐PVI‐ONLY) vs. 92.8% (RF‐PVI+PWI); p = 0.88]. Arrhythmia recurrence was significantly more common in the CRYO‐PVI‐ONLY group (39.7%) compared to RF‐PVI+PWI (27.7 %); p = 0.03. Comparable results were observed in paroxysmal and persistent AF. Conclusion: CRYO‐PVI‐ONLY and RF‐PVI+PWI resulted in comparable improvements in patient reported outcomes including QoL and AF burden; with RF‐PVI+PWI being more effective at reducing recurrences.
- Open Access
- 26 July 2023
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (8) , 1648-1657
Impact of obesity on catheter ablation of atrial fibrillation: Patient characteristics, procedural complications, outcomes, and quality of life
Introduction: Obesity is a well‐known risk factor for atrial fibrillation (AF). We aim to evaluate the effect of baseline obesity on procedural complications, AF recurrence, and symptoms following catheter ablation (CA).Methods: All consecutive patients undergoing AF ablation (2013–2021) at our center were enrolled in a prospective registry. The study included all consecutive patients with available data on body mass index (BMI). Primary endpoint was AF recurrence based on electrocardiographic documentation. Patients were categorized into five groups according to their baseline BMI. Patients survey at baseline and at follow‐up were used to calculate AF symptom severity score (AFSS) as well as AF burden (mean of AF duration score and AF frequency score; scale 0: no AF to 10: continuous and 9 frequencies/durations in between). Patients were scheduled for follow‐up visits with 12‐lead electrocardiogram at 3, 6, and 12 months after ablation, and every 6 months thereafter.Results: A total of 5841 patients were included (17% normal weight, 34% overweight, 27% Class I, 13% Class II, and 9% Class III obesity). Major procedural complications were low (1.5%) among all BMI subgroups. At 3 years AF recurrence was the highest in Class III obesity patients (48%) followed by Class II (43%), whereas Class I, normal, and overweight had similar results with lower recurrence (35%). In multivariable analyses, Class III obesity (BMI ≥ 40) was independently associated with increased risk for AF recurrence (hazard ratio, 1.30; confidence interval, 1.06–1.60; p = .01), whereas other groups had similar risk in comparison to normal weight. Baseline AFSS was lowest in normal weight, and highest in Obesity‐III, median (interquartile range) 10 (5–16) versus 15 (10–21). In all groups, CA resulted in a significant improvement in their AFSS with a similar magnitude among the groups. At follow‐up, AF burden was minimal and did not differ significantly between the groups.Conclusion: AF ablation is safe with a low complication rate across all BMI groups. Morbid obesity (BMI ≥ 40) was significantly associated with reduced AF ablation success. However, ablation resulted in improvement in QoL including reduction of the AFSS, and AF burden regardless of BMI.
- 26 July 2023
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (8) , 1648-1657
Open AccessImpact of obesity on catheter ablation of atrial fibrillation: Patient characteristics, procedural complications, outcomes, and quality of life
Introduction: Obesity is a well‐known risk factor for atrial fibrillation (AF). We aim to evaluate the effect of baseline obesity on procedural complications, AF recurrence, and symptoms following catheter ablation (CA).Methods: All consecutive patients undergoing AF ablation (2013–2021) at our center were enrolled in a prospective registry. The study included all consecutive patients with available data on body mass index (BMI). Primary endpoint was AF recurrence based on electrocardiographic documentation. Patients were categorized into five groups according to their baseline BMI. Patients survey at baseline and at follow‐up were used to calculate AF symptom severity score (AFSS) as well as AF burden (mean of AF duration score and AF frequency score; scale 0: no AF to 10: continuous and 9 frequencies/durations in between). Patients were scheduled for follow‐up visits with 12‐lead electrocardiogram at 3, 6, and 12 months after ablation, and every 6 months thereafter.Results: A total of 5841 patients were included (17% normal weight, 34% overweight, 27% Class I, 13% Class II, and 9% Class III obesity). Major procedural complications were low (1.5%) among all BMI subgroups. At 3 years AF recurrence was the highest in Class III obesity patients (48%) followed by Class II (43%), whereas Class I, normal, and overweight had similar results with lower recurrence (35%). In multivariable analyses, Class III obesity (BMI ≥ 40) was independently associated with increased risk for AF recurrence (hazard ratio, 1.30; confidence interval, 1.06–1.60; p = .01), whereas other groups had similar risk in comparison to normal weight. Baseline AFSS was lowest in normal weight, and highest in Obesity‐III, median (interquartile range) 10 (5–16) versus 15 (10–21). In all groups, CA resulted in a significant improvement in their AFSS with a similar magnitude among the groups. At follow‐up, AF burden was minimal and did not differ significantly between the groups.Conclusion: AF ablation is safe with a low complication rate across all BMI groups. Morbid obesity (BMI ≥ 40) was significantly associated with reduced AF ablation success. However, ablation resulted in improvement in QoL including reduction of the AFSS, and AF burden regardless of BMI.
- 1 June 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (6) , 361-369
Atrial Fibrillation Ablation in Young Adults: Measuring Quality of Life Using Patient-Reported Outcomes Over 5 Years
Background: Ablation is used for both rhythm control and improved quality of life (QoL) in atrial fibrillation (AF). It has been suggested that young adults may experience high recurrence rates after ablation and data remain lacking regarding QoL benefits. We aimed to investigate AF ablation outcomes and QoL benefits in young adults undergoing AF ablation using a large prospectively maintained registry and automated patient-reported outcomes (PRO). Methods: All patients undergoing AF ablation (2013–2016) at our center were prospectively enrolled. Patients aged 50 years or younger were included. For PROs, QoL measures and symptoms were assessed at baseline, 3 months after ablation, and every 6 months thereafter. The AF severity score served as the main assessment of QoL. Results: A total of 241 young adults (age, 16–50 years) were included (17% female, 40.3% persistent AF). In all, 77.2% of patients remained arrhythmia-free during the first year of follow-up (80% in nonstructural AF and 66% in structural AF). Using PROs, 90% of patients reported improvement in QoL throughout all survey time points up to 5 years postablation ( P P P <0.0001). Conclusions: Ablation remains an effective rhythm-control strategy in young adults with AF. Young adults also experience significant improvement in QoL with reduction of the frequency and duration of AF episodes and AF-related healthcare utilization.
- 1 June 2023
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 16 (6) , 361-369
Atrial Fibrillation Ablation in Young Adults: Measuring Quality of Life Using Patient-Reported Outcomes Over 5 Years
Background: Ablation is used for both rhythm control and improved quality of life (QoL) in atrial fibrillation (AF). It has been suggested that young adults may experience high recurrence rates after ablation and data remain lacking regarding QoL benefits. We aimed to investigate AF ablation outcomes and QoL benefits in young adults undergoing AF ablation using a large prospectively maintained registry and automated patient-reported outcomes (PRO). Methods: All patients undergoing AF ablation (2013–2016) at our center were prospectively enrolled. Patients aged 50 years or younger were included. For PROs, QoL measures and symptoms were assessed at baseline, 3 months after ablation, and every 6 months thereafter. The AF severity score served as the main assessment of QoL. Results: A total of 241 young adults (age, 16–50 years) were included (17% female, 40.3% persistent AF). In all, 77.2% of patients remained arrhythmia-free during the first year of follow-up (80% in nonstructural AF and 66% in structural AF). Using PROs, 90% of patients reported improvement in QoL throughout all survey time points up to 5 years postablation ( P P P <0.0001). Conclusions: Ablation remains an effective rhythm-control strategy in young adults with AF. Young adults also experience significant improvement in QoL with reduction of the frequency and duration of AF episodes and AF-related healthcare utilization.
- Open Access
Impact of Obesity on Catheter Ablation of Atrial fibrillation: Patient Characteristics, Procedural Complications, Outcomes and Quality of Life
Background Obesity is a well-known risk factor for atrial fibrillation (AF). Objective To evaluate the effect of baseline obesity on procedural complications, AF recurrence, and symptoms following catheter ablation (CA). Methods A total of 5841 patients undergoing AF ablation (2013-2021) were enrolled in a prospectively maintained registry. Primary endpoint was AF recurrence based on electrocardiographic documentation. Patients were categorized into 5 groups according to their baseline body mass index (BMI). Patients survey at baseline and at follow-up were used to calculate AF severity score (AFSS) as well as AF burden. Results Major procedural complications were low (1.5%) among BMI sub-groups. At 3 years AF recurrence was highest in Class III obesity patients (48%) followed by Class II (43%), whereas Class I, normal, and overweight had similar results with lower recurrence (35%). In multivariable analyses, Class III obesity was independently associated with increased risk for AF recurrence (HR=1.30, P=0.01), whereas other groups had similar risk in comparison to normal weight. Baseline AFSS was lowest in normal weight, and highest in Obesity-III, median [interquartile range] 10 [5-16] vs 15 [10-21]. In all groups, CA resulted in improvement in their AFSS with a similar magnitude among the groups. At follow-up, AF burden was minimal and did not differ significantly between the groups. Conclusion AF ablation is safe with a low complication rate across all BMI groups. Morbid obesity (BMI ≥40) was significantly associated with reduced AF ablation success. However, ablation resulted in improvement in QOL including reduction of the AFSS, and AF burden. What is known? Obesity is an independent risk factor of atrial fibrillation (AF) Catheter ablation (CA) has emerged as a standard of care in arrhythmia management, leading to improvements in quality of life, reductions in hospitalizations, and potential reductions in major adverse clinical outcomes. What is known?More obese patients are being referred to catheter ablation of AF. What is new? AF ablation is safe with low complication rates across all BMI sub-groups (<1.5%) Morbid obesity (BMI ≥40) was associated with increased risk of AF recurrence after ablation Using patient reported outcomes, AF Ablation resulted in improvement of quality of life regardless of BMI
Open AccessImpact of Obesity on Catheter Ablation of Atrial fibrillation: Patient Characteristics, Procedural Complications, Outcomes and Quality of Life
Background Obesity is a well-known risk factor for atrial fibrillation (AF). Objective To evaluate the effect of baseline obesity on procedural complications, AF recurrence, and symptoms following catheter ablation (CA). Methods A total of 5841 patients undergoing AF ablation (2013-2021) were enrolled in a prospectively maintained registry. Primary endpoint was AF recurrence based on electrocardiographic documentation. Patients were categorized into 5 groups according to their baseline body mass index (BMI). Patients survey at baseline and at follow-up were used to calculate AF severity score (AFSS) as well as AF burden. Results Major procedural complications were low (1.5%) among BMI sub-groups. At 3 years AF recurrence was highest in Class III obesity patients (48%) followed by Class II (43%), whereas Class I, normal, and overweight had similar results with lower recurrence (35%). In multivariable analyses, Class III obesity was independently associated with increased risk for AF recurrence (HR=1.30, P=0.01), whereas other groups had similar risk in comparison to normal weight. Baseline AFSS was lowest in normal weight, and highest in Obesity-III, median [interquartile range] 10 [5-16] vs 15 [10-21]. In all groups, CA resulted in improvement in their AFSS with a similar magnitude among the groups. At follow-up, AF burden was minimal and did not differ significantly between the groups. Conclusion AF ablation is safe with a low complication rate across all BMI groups. Morbid obesity (BMI ≥40) was significantly associated with reduced AF ablation success. However, ablation resulted in improvement in QOL including reduction of the AFSS, and AF burden. What is known? Obesity is an independent risk factor of atrial fibrillation (AF) Catheter ablation (CA) has emerged as a standard of care in arrhythmia management, leading to improvements in quality of life, reductions in hospitalizations, and potential reductions in major adverse clinical outcomes. What is known?More obese patients are being referred to catheter ablation of AF. What is new? AF ablation is safe with low complication rates across all BMI sub-groups (<1.5%) Morbid obesity (BMI ≥40) was associated with increased risk of AF recurrence after ablation Using patient reported outcomes, AF Ablation resulted in improvement of quality of life regardless of BMI
- 2 November 2022
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (1) , 54-61
Impact of redo ablation for atrial fibrillation on patient‐reported outcomes and quality of life
Introduction: Catheter ablation for atrial fibrillation (AF) is frequently used for the purpose of rhythm control and improved quality of life (QoL). Although success rates are high, a significant proportion of patients require redo ablation. Data are scarce on patient‐centered outcomes and QoL in patients undergoing redo AF ablation. We aimed to assess QoL and clinical outcomes using a large prospectively maintained patient‐reported outcomes (PRO) registry.Methods: All patients undergoing redo AF ablation (2013–2016) at our center were enrolled in a prospective registry for outcomes and assessed for QoL using automated PRO surveys (baseline, 3 and 6 months after ablation, every 6 months thereafter). Data were collected over 3 years of follow‐up. The atrial fibrillation symptom severity scale (AFSSS) was used as the main measure for QoL. Additional variables included patient‐reported improvement, AF burden, and AF‐related healthcare utilization including emergency room (ER) visits and hospitalizations.Results: A total of 848 patients were included (28% females, mean age 63.8, 51% persistent AF). By automated PRO, significant improvement in QoL was noted (baseline median AFSSS of 12 [5–18] and ranged between 2 and 4 on subsequent assessments; p < .0001), with ≥70%of patients reported remarkable improvement in their AF‐related symptoms. The proportion of patients in AF at the time of baseline survey was 36%, and this decreased to p < .0001). AF burden was significantly reduced (including frequency and duration of episodes; p < .0001), with an associated decrease in healthcare utilization after 6 months from the time of ablation (including ER visits and hospitalizations; p < .0001). The proportion of patients on anticoagulants or antiarrhythmics decreased on follow‐up across all time points (p < .0001 for all variables).Conclusion: Most patients derive significant QoL benefit from redo AF ablation; with reduction of both AF burden and healthcare utilization.
- 2 November 2022
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 34 (1) , 54-61
Impact of redo ablation for atrial fibrillation on patient‐reported outcomes and quality of life
Introduction: Catheter ablation for atrial fibrillation (AF) is frequently used for the purpose of rhythm control and improved quality of life (QoL). Although success rates are high, a significant proportion of patients require redo ablation. Data are scarce on patient‐centered outcomes and QoL in patients undergoing redo AF ablation. We aimed to assess QoL and clinical outcomes using a large prospectively maintained patient‐reported outcomes (PRO) registry.Methods: All patients undergoing redo AF ablation (2013–2016) at our center were enrolled in a prospective registry for outcomes and assessed for QoL using automated PRO surveys (baseline, 3 and 6 months after ablation, every 6 months thereafter). Data were collected over 3 years of follow‐up. The atrial fibrillation symptom severity scale (AFSSS) was used as the main measure for QoL. Additional variables included patient‐reported improvement, AF burden, and AF‐related healthcare utilization including emergency room (ER) visits and hospitalizations.Results: A total of 848 patients were included (28% females, mean age 63.8, 51% persistent AF). By automated PRO, significant improvement in QoL was noted (baseline median AFSSS of 12 [5–18] and ranged between 2 and 4 on subsequent assessments; p < .0001), with ≥70%of patients reported remarkable improvement in their AF‐related symptoms. The proportion of patients in AF at the time of baseline survey was 36%, and this decreased to p < .0001). AF burden was significantly reduced (including frequency and duration of episodes; p < .0001), with an associated decrease in healthcare utilization after 6 months from the time of ablation (including ER visits and hospitalizations; p < .0001). The proportion of patients on anticoagulants or antiarrhythmics decreased on follow‐up across all time points (p < .0001 for all variables).Conclusion: Most patients derive significant QoL benefit from redo AF ablation; with reduction of both AF burden and healthcare utilization.
- Open Access
- 5 August 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (16) , e024574
Short‐Term Outcomes Following Left Atrial Appendage Closure in the Very Elderly: A Population‐Based Analysis
Background: Data on percutaneous left atrial appendage closure (LAAC) outcomes in the very elderly with atrial fibrillation are limited. We aimed to investigate the clinical characteristics and short‐term outcomes of patients 80 years or older following percutaneous LAAC in a large nationwide database. Methods and Results: Using the Nationwide Readmissions Database, we identified patients who underwent percutaneous LAAC between January 2016 and December 2018. Patients were categorized based on age (≥80 and P =0.236. Rates of in‐hospital stroke/transient ischemic attack were higher in patients ≥80 years old compared with those P =0.009). In‐hospital bleeding requiring transfusion, vascular complications, systemic embolization, and pericardial effusion/tamponade requiring pericardiocentesis or surgical intervention occurred more frequently in patients ≥80 years old. Furthermore, the elderly group was more likely to be readmitted within 30 days compared with those P =0.004); however, rates of 30‐day complications were not statistically different between the study groups. Conclusions: In a large nationwide database, patients ≥80 years old undergoing percutaneous LAAC were found to have similar in‐hospital mortality but an increased risk of periprocedural complications and 30‐day readmission compared with younger patients. Our data suggest that LAAC should be considered on a case‐by‐case basis in the very elderly, taking into consideration the risks and benefits of this intervention. Further studies are needed to assess long‐term LAAC outcomes in this high‐risk population.
- 5 August 2022
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 11 (16) , e024574
Open AccessShort‐Term Outcomes Following Left Atrial Appendage Closure in the Very Elderly: A Population‐Based Analysis
Background: Data on percutaneous left atrial appendage closure (LAAC) outcomes in the very elderly with atrial fibrillation are limited. We aimed to investigate the clinical characteristics and short‐term outcomes of patients 80 years or older following percutaneous LAAC in a large nationwide database. Methods and Results: Using the Nationwide Readmissions Database, we identified patients who underwent percutaneous LAAC between January 2016 and December 2018. Patients were categorized based on age (≥80 and P =0.236. Rates of in‐hospital stroke/transient ischemic attack were higher in patients ≥80 years old compared with those P =0.009). In‐hospital bleeding requiring transfusion, vascular complications, systemic embolization, and pericardial effusion/tamponade requiring pericardiocentesis or surgical intervention occurred more frequently in patients ≥80 years old. Furthermore, the elderly group was more likely to be readmitted within 30 days compared with those P =0.004); however, rates of 30‐day complications were not statistically different between the study groups. Conclusions: In a large nationwide database, patients ≥80 years old undergoing percutaneous LAAC were found to have similar in‐hospital mortality but an increased risk of periprocedural complications and 30‐day readmission compared with younger patients. Our data suggest that LAAC should be considered on a case‐by‐case basis in the very elderly, taking into consideration the risks and benefits of this intervention. Further studies are needed to assess long‐term LAAC outcomes in this high‐risk population.
- 1 January 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 162, 207-209
Gender Differences in the Outcomes of Transcatheter Mitral Valve Implantation
- 1 January 2022
- Published by Elsevier in The American Journal of Cardiology
- Vol. 162, 207-209
Gender Differences in the Outcomes of Transcatheter Mitral Valve Implantation
- 1 August 2021
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 14 (8)
Super and Nonresponders to Catheter Ablation for Atrial Fibrillation: A Quality-of-Life Assessment Using Patient Reported Outcomes
Background: Atrial fibrillation (AF) ablation targets improvement in quality of life (QoL). Data is scarce on predictors of QoL improvement following ablation. We aimed to investigate the clinical characteristics underlying differential response in QoL after AF ablation (with or without arrhythmia recurrence). Methods: All patients undergoing AF ablation (2013–2016) at our center were prospectively enrolled in a fully automated patient-reported outcomes registry. A large number of variables were collected including AF symptom severity scale and AF burden (as indicated by AF frequency and duration scores). Patients were divided into 3 groups based on self-report of QoL improvement: remarkable (super responders), mild/moderate, and unchanged or worse (nonresponders). Univariable and multivariable logistic regression models assessed clinical characteristics and QoL outcomes. Results: A total of 956 patients were included (25% females, mean age 63.9). Most patients (≈80%) were super responders (n=761), 138 (14.4%) had mild/moderate improvement, and 57 (5.9%) were nonresponders. The strongest predictors of remarkable QoL improvement were freedom of arrhythmia recurrence (OR, 2.42 [95% CI, 1.27–4.59], P =0.007) and lower AF burden at 12 months. Similarly, higher AF burden was significantly associated with clinical nonresponse. In patients with observed clinical recurrence-QoL mismatch, changes in AF burden at 12 months were the main predictors of QoL outcome, with lower burden predicting higher improvement in QoL and vice versa. Conclusions: Most patients derive significant QoL benefit from AF ablation. Freedom from arrhythmia recurrence and lower AF burden predict remarkable QoL improvement following ablation.
- 1 August 2021
- Published by Wolters Kluwer Health in Circulation: Arrhythmia and Electrophysiology
- Vol. 14 (8)
Super and Nonresponders to Catheter Ablation for Atrial Fibrillation: A Quality-of-Life Assessment Using Patient Reported Outcomes
Background: Atrial fibrillation (AF) ablation targets improvement in quality of life (QoL). Data is scarce on predictors of QoL improvement following ablation. We aimed to investigate the clinical characteristics underlying differential response in QoL after AF ablation (with or without arrhythmia recurrence). Methods: All patients undergoing AF ablation (2013–2016) at our center were prospectively enrolled in a fully automated patient-reported outcomes registry. A large number of variables were collected including AF symptom severity scale and AF burden (as indicated by AF frequency and duration scores). Patients were divided into 3 groups based on self-report of QoL improvement: remarkable (super responders), mild/moderate, and unchanged or worse (nonresponders). Univariable and multivariable logistic regression models assessed clinical characteristics and QoL outcomes. Results: A total of 956 patients were included (25% females, mean age 63.9). Most patients (≈80%) were super responders (n=761), 138 (14.4%) had mild/moderate improvement, and 57 (5.9%) were nonresponders. The strongest predictors of remarkable QoL improvement were freedom of arrhythmia recurrence (OR, 2.42 [95% CI, 1.27–4.59], P =0.007) and lower AF burden at 12 months. Similarly, higher AF burden was significantly associated with clinical nonresponse. In patients with observed clinical recurrence-QoL mismatch, changes in AF burden at 12 months were the main predictors of QoL outcome, with lower burden predicting higher improvement in QoL and vice versa. Conclusions: Most patients derive significant QoL benefit from AF ablation. Freedom from arrhythmia recurrence and lower AF burden predict remarkable QoL improvement following ablation.